Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Innovent Biologics and IASO Biotherapeutics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress
2021-06-08 08:00
Live from ASCO 2021 | Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and Safety of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed or Refractory CLL/SLL
2021-06-08 07:30
Live from ASCO 2021 | Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs
2021-06-08 07:21
Second Global Health Forum of Boao Forum for Asia: A Call for Innovation and Collaboration to Promote the Progress of the Global Health System
2021-06-07 21:35
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in the United States and Puerto Rico
2021-06-07 21:00
Elekta's new strategy to focus on growth and access to radiation therapy
2021-06-07 20:44
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study
2021-06-07 19:00
Device Companies will Drive Surgery Automation to Increase Elective Procedures in Western Europe
2021-06-07 18:02
L'OCCITANE Race for Vision 2021: United Against Blindness
2021-06-07 17:21
Clarivate Forecasts Nearly 70% of North American, European and Asia Pacific Adult Populations Will Be Vaccinated for COVID-19 by September 2021
2021-06-07 16:15
Elekta and Philips deepen strategic partnership in precise and individualized oncology care
2021-06-07 16:02
Alodokter Raises Fresh Capital from MDI Ventures and Samsung Ventures to Grow Ecosystem
2021-06-07 13:26
Cigna Study Shows Uncertainty about the Future Continues to be the Leading Cause of Stress
2021-06-07 12:00
China makes great efforts to contain COVID-19, saves more lives: SCO Secretary-General
2021-06-07 11:35
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021
2021-06-07 10:11
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021
2021-06-07 10:10
BIAL Award in Biomedicine worth 300,000 Euros, nominations until 30 June
2021-06-07 10:00
Hyperice Named Official Recovery Technology Partner by League of Legends Pro League
2021-06-07 10:00
OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting
2021-06-07 10:00
Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021
2021-06-07 09:53
1
324
325
326
327
328
738